ResearcherHarvard UniversityActive in the last 2 years
Kevin Sheng‐Kai Ma
Matched on ORCID iD 0000-0002-9394-4144; OpenAlex author ID A5077608235. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2022: 1 paper · 2023: none · 2024: 1 paper
Papers 2
- Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: A systematic review and meta-analysis. Last author DOI 10.1016/j.critrevonc.2024.104386↗
- The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adeno… Co-author DOI 10.1097/mpa.0000000000002125↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Brian Shiian Chen · 2 shared papers, 2022–2024 · strength 0.41
- Paper Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: A systematic r… DOI 10.1016/j.critrevonc.2024.104386↗
- Paper The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanc… DOI 10.1097/mpa.0000000000002125↗
- Cho‐Han Chiang · 1 shared paper, 2022 · strength 0.15
- Cheng‐Ming Peng · 1 shared paper, 2022 · strength 0.15
- Yu‐Ze Luan · 1 shared paper, 2022 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.